This is reflected in the summary of clinical recommendations on the use of insulin mixtures in the treatment of type 2 diabetes, indicating that in some patients Mix50 mixtures may be more appropriate than Mix25/30 mixtures, and clinicians should consider not only efficacy and safety, but also traits and patient preferences during insulin treatment of people with type 2 diabetes [63]. This evidence concerns the gene INS and type 2 diabetes mellitus.